Who are The RP group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Edarbi, Cozaar, Alphintern® , tablet, Amoun, Egypt, Candesartan cilexetil / hydrochlorothiazide, olmesartan medoxomil + hydrochlorothiazide, if necessary, MIR.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/the-rp-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

The RP group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The RP group (The RP group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin receptor blockers (ARBs). Area: Cardiovascular.

marketed Angiotensin receptor blockers (ARBs) AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

The RP group (The RP group) — Beijing Tiantan Hospital. The RP group is a class of drugs that inhibit the renin-angiotensin system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
The RP group TARGET	The RP group	Beijing Tiantan Hospital	marketed	Angiotensin receptor blockers (ARBs)	AT1 receptor
Edarbi	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
Alphintern® , tablet, Amoun, Egypt	Alphintern® , tablet, Amoun, Egypt	Ain Shams University	marketed	Angiotensin II receptor antagonist	AT1 receptor
Candesartan cilexetil / hydrochlorothiazide	Candesartan cilexetil / hydrochlorothiazide	Takeda	marketed	Angiotensin II receptor antagonist / thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
olmesartan medoxomil + hydrochlorothiazide, if necessary	olmesartan medoxomil + hydrochlorothiazide, if necessary	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
MIR	MIR	Rambam Health Care Campus	marketed	Angiotensin receptor blocker	AT1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin receptor blockers (ARBs) class)

Beijing Tiantan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). The RP group — Competitive Intelligence Brief. https://druglandscape.com/ci/the-rp-group. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing